Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

• Status: Completed
• Trial end date: 2015-04-01

Summary

The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.

The primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).

• Phase: Phase 3

Details

• Lead Sponsor: ALK-Abelló A/S; Merck Sharp & Dohme Corp.
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Epinephrine; Epinephryl borate; Loratadine; Mometasone Furoate; Olopatadine Hydrochloride; Ophthalmic Solutions; Racepinephrine